Lenalidomide,Idecabtagene vicleucel
BMS,2Seventy Bio
['mmsm', 'karmma', 'karmma-2']
functional high risk patients - suboptimal response after frontline therapy
use of karmma-2 in this patient population #mmsm
#asco2023 
Multiple Myeloma Specialist  at UTSW Harold C. Simmons Comprehensive Cancer Center | Montefiore  & Tufts Alum